The FINANCIAL -- Raritan, NJ (October 5, 2011) – Today Scios Inc. announced an agreement
with the United States Department of Justice to resolve allegations of
misbranding of NATRECOR® (nesiritide), a prescription medication for
patients with heart failure.
As part of this agreement, Scios Inc. entered a guilty plea to a single misdemeanor violation of the Food, Drug and Cosmetic Act, and agreed to pay an $85 million fine.
Scios acknowledges that NATRECOR® was misbranded and used in a way not approved by the U.S. Food and Drug Administration because its labeling lacked adequate directions for that use, but denies any wrongful intent in connection with this plea.
Related Stories
